AURKB and pachyonychia congenita: Currently, research is being done on AURKB as a potential therapeutic target for several tumour types, including leukemia, prostate cancer (PC), gastric cancer (GC), breast cancer, and non-small cell lung cancer (NSCLC) [48–52].